The Division of Nephrology and Hypertension, Department of Internal Medicine, FMUI/RSCM will host an annual scientific meeting, the “Jakarta Nephrology Meeting (JNM) 2024”. This meeting acts as an effort to improve the knowledge and competencies of general practitioners, internists, and nephrologists, as well as those from other related disciplines in the nephrology and hypertension fields. The JNM is being held for the sixth time this year, featuring new and updated intriguing topics.

This year’s JNM theme is “Improving Quality of Care in End-Stage Kidney Disease,” which intends to study extensively topics associated with chronic kidney disease, with a highlight in end-stage kidney disease (ESKD) and its updated standard of care. Recently, incidence rates of treated ESKD were relatively stable in many higher-income countries but rose substantially predominantly in East and Southeast Asia. The prevalence of treated ESKD has increased worldwide, likely due to improving ESKD survival, population demographic shifts, higher prevalence of ESKD risk factors, and increasing KRT access in countries with growing economies. The morbidity and mortality of ESKD patients are still high, with a mortality is around 22%. This high morbidity and mortality can be reduced significantly by performing good quality kidney replacement therapy (KRT) based on individual preference (hemodialysis/HD, continuous ambulatory peritoneal dialysis/CAPD, kidney transplant, and conservative treatment).

Many people worldwide in need of KRT as a life-sustaining treatment do not receive it, mostly in Low Middle-Income Countries (LMIC) where healthcare resources are severely limited. This large treatment gap demands a focus on population-based prevention strategies and the development of affordable and cost-effective KRT. Strategies to reduce ESKD burden and KRT access inequities at a provider level include early CKD detection, prevention and treatment programs with attention to education and lifestyle intervention, communicable diseases, non-communicable diseases (hypertension, diabetes, obesity, and cardiovascular disease), and avoidance of nephrotoxic agents (including over-the-counter and non-traditional remedies). Thus, comprehensive management and a multidisciplinary approach are needed to improve the outcomes and quality of life of ESKD patients.

JNM 2024 will cover various scientific activities including workshops, plenary lectures, meet the experts, and symposia that will be delivered by experts in the field of nephrology and other related disciplines. JNM 2024 will also carry an engaging and interactive scientific event to achieve the best standard of care for ESKD patients. Exhibitions from pharmaceutical and medical device companies will also liven up this event.

Therefore, the JNM 2024 committee extends an invitation to colleagues and pharmaceutical industries to contribute and support this event. We sincerely appreciate your support and collaboration.